Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise 2022-04-19 09:19
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022 2022-04-13 06:00
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting 2022-03-10 07:00
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases 2022-03-08 08:00
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics 2022-02-08 06:00
Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China 2021-10-20 07:00
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 2021-09-17 06:00
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis 2021-06-14 06:00
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site 2021-06-02 06:00
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S 2021-04-07 06:00
Termination of Bridge Biotherapeutics's Collaboration and License Agreement with Boehringer Ingelheim 2020-11-09 18:07
Bridge Biotherapeutics becomes BaseLaunch's first Asia Pacific partner 2020-07-15 07:00
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea 2020-05-08 07:30
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis 2020-04-09 15:14
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC 2019-12-27 06:30
1 2